메뉴 건너뛰기




Volumn 39, Issue 2, 2016, Pages 231-241

A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; LIRAGLUTIDE; PLACEBO; SEMAGLUTIDE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

EID: 84962052845     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0165     Document Type: Article
Times cited : (170)

References (17)
  • 1
    • 33846006173 scopus 로고    scopus 로고
    • The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
    • Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705
    • (2006) Lancet , vol.368 , pp. 1696-1705
    • Drucker, D.J.1    Nauck, M.A.2
  • 2
    • 0032005005 scopus 로고    scopus 로고
    • Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans
    • Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101: 515-520
    • (1998) J Clin Invest , vol.101 , pp. 515-520
    • Flint, A.1    Raben, A.2    Astrup, A.3    Holst, J.J.4
  • 3
    • 0033021677 scopus 로고    scopus 로고
    • Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men
    • Naslund E, Barkeling B, King N, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 1999;23:304-311
    • (1999) Int J Obes Relat Metab Disord , vol.23 , pp. 304-311
    • Naslund, E.1    Barkeling, B.2    King, N.3
  • 4
    • 0030068620 scopus 로고    scopus 로고
    • Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients
    • Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996;81:327-332
    • (1996) J Clin Endocrinol Metab , Issue.81 , pp. 327-332
    • Willms, B.1    Werner, J.2    Holst, J.J.3    Orskov, C.4    Creutzfeldt, W.5    Nauck, M.A.6
  • 5
    • 84879418684 scopus 로고    scopus 로고
    • Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity
    • Lorenz M, Evers A, Wagner M. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity. Bioorg Med Chem Lett 2013;23: 4011-4018
    • (2013) Bioorg Med Chem Lett , vol.23 , pp. 4011-4018
    • Lorenz, M.1    Evers, A.2    Wagner, M.3
  • 6
    • 84926012859 scopus 로고    scopus 로고
    • Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bio-availability of the combined oral contraceptive, ethinylestradiol/levonorgestrel
    • Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bio-availability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol 2015;55:497-504
    • (2015) J Clin Pharmacol , vol.55 , pp. 497-504
    • Kapitza, C.1    Nosek, L.2    Jensen, L.3    Hartvig, H.4    Jensen, C.B.5    Flint, A.6
  • 7
    • 84962096931 scopus 로고    scopus 로고
    • Pharmacokinetics and tolerability of a single dose of semaglutide, a once-weekly human GLP-1 analog, in subjects with and without renal impairment
    • Marbury TC, Flint A, Segel S, Lindegaard M, Lasseter KC. Pharmacokinetics and tolerability of a single dose of semaglutide, a once-weekly human GLP-1 analog, in subjects with and without renal impairment. Diabetologia 2014;57(Suppl. 1): S358
    • (2014) Diabetologia , vol.57 , pp. S358
    • Marbury, T.C.1    Flint, A.2    Segel, S.3    Lindegaard, M.4    Lasseter, K.C.5
  • 10
    • 77649091668 scopus 로고    scopus 로고
    • American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes melli-tus
    • Rodbard HW, Blonde L, Braithwaite SS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes melli-tus. Endocrine Pract 2007;13(Suppl. 1):1-68
    • (2007) Endocrine Pract , vol.13 , pp. 1-68
    • Rodbard, H.W.1    Blonde, L.2    Braithwaite, S.S.3
  • 11
    • 84892649479 scopus 로고    scopus 로고
    • Standards of medical care in diabetes-2014
    • American Diabetes Association.
    • American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014;37(Suppl. 1):S14-S80
    • (2014) Diabetes Care , vol.37 , pp. S14-S80
  • 15
    • 84881560141 scopus 로고    scopus 로고
    • Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?
    • Nauck MA, Baranov O, Ritzel RA, Meier JJ. Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation? Diabetologia 2013;56: 1878-1883
    • (2013) Diabetologia , vol.56 , pp. 1878-1883
    • Nauck, M.A.1    Baranov, O.2    Ritzel, R.A.3    Meier, J.J.4
  • 16
    • 0034935081 scopus 로고    scopus 로고
    • Measurements of the gastric emptying rate by use of ultrasonography: Studiesin humans using bread with added sodium propionate
    • Darwiche G, Ostman EM, Liljeberg HG, et al. Measurements of the gastric emptying rate by use of ultrasonography: studiesin humans using bread with added sodium propionate. Am J Clin Nutr 2001;74:254-258
    • (2001) Am J Clin Nutr , vol.74 , pp. 254-258
    • Darwiche, G.1    Ostman, E.M.2    Liljeberg, H.G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.